Cipla (CIPLA) Q4 20/21 earnings summary

Executive summary

• FY21 consolidated revenue rose 12% YoY to ₹19,160 crore; resilient supply and growth across geographies offset pandemic disruption and the discontinued MEIS export benefit.

• Record EBITDA margin of 22.5% and PAT of ₹2,405 crore reflected cost discipline, portfolio execution and strong demand for COVID-19 products.

• Strategy centers on branded-market growth, respiratory leadership, complex generics, digital transformation, supply consistency and sustainable margin expansion.

Financial highlights

• Revenue from operations was ₹19,160 crore, up 12% YoY; five-year revenue CAGR was 7%.

• EBITDA was ₹4,303 crore versus ₹3,230 crore; reported EBITDA margin increased to 22.5% from 18.9%, up 350+ bps YoY.

• PAT was ₹2,405 crore versus ₹1,547 crore, up 55% YoY; PAT margin reached 12.6% versus 9.0%.

• Diluted EPS was ₹29.79 versus ₹19.16; operating cash flow reached ₹3,755 crore and free cash flow ₹2,856 crore versus ₹1,955 crore.

• FY21 reported EBITDA included one-time litigation settlement income; the settlement was recorded in other income.

Outlook and guidance

• FY22 priorities: maintain uninterrupted COVID-19 and non-COVID-19 supply, execute critical launches, grow core businesses, improve productivity and preserve cost discipline.

• Management aims to retain a good share of structural operating improvements in FY22 while continuing investment in growth opportunities.

• R&D spend is expected to increase as selected respiratory assets enter clinical trials; priority projects and filings remain on track.

• Outlook remains subject to the uncertain pandemic trajectory, changing demand patterns and supply-chain disruption.